Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New tool aims to help doctors and nurses track their own performance

NCT ID NCT07179289

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a tool called MSProgress that gives healthcare teams easy access to their own data, like how well they are doing on certain health measures. The tool is a simple 20-page report with 43 indicators that teams can choose from. The goal is to see if using this tool helps teams improve their care over time. Sixty healthcare centers in France will take part, and researchers will track their progress for several years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MSProgress quality approach support tool (a 20-page document with 43 indicators from health insurance databases)
What this could lead to
If it works, this could help healthcare teams improve their practices by easily tracking their own performance over time.
What could go wrong
This is a small, early-stage study with only 60 teams. The tool may not lead to meaningful improvements, and results may not apply to other regions or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

MSP dans la région Auvergne-Rhône-Alpes. For the randomized controlled trial, the statistical individual is the patient. The data used and transmitted by the French National Health Insurance are statistical data that do not allow patients to be identified but simply to identify a number of patients concerned by the indicator chosen by the teams.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All MSPs in the Auvergne-Rhône-Alpes region that signed the Interprofessional Conventional Agreement (ICA) before October 31, 2023, granting the research team, through team consent, access to their data from the French National Health Insurance databases from 2021 to 2027, volunteer to participate in the MSProgress research project. * Additional specific criteria for the qualitative study: After randomization of the 60 MSPs for the cluster randomized controlled trial, among the first established group named "MSProgress 2024," volunteer MSPs will be able to participate in the qualitative study. To do so, professionals agree to participate in three semi-structured group interviews (one per year over the three years of the study), by signing an individual consent form. We will ensure that the MSPs included are representative of the diversity of MSP profiles: * Territory and patient population: rural; peri-urban; urban; priority neighborhoods of the city policy; * Team size: "large MSP" defined as a team of \> 15 healthcare professionals; "small MSP" defined as a team of \< 15 healthcare professionals; * Site configuration: single-site; multi-site; * Length of time the ACI was signed: "old team" having signed the ACI more than 3 years ago; "young team" having signed the ACI less than 3 years ago. Exclusion Criteria: * MSPs in the Auvergne-Rhône-Alpes region that have not signed the ICA before October 31, 2023.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Evaluation of the impact of the msprogress quality approach support tool on the evolution of the indicators chosen by the MSPS in comparison with standard care are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital, Clermont-Ferrand

    Clermont-Ferrand, Auvergne-Rhône-Alpes, France, France